Chronic obstructive pulmonary disease (COPD) is the most common respiratory disorder of adults in the developed world and is the fourth main cause of death in the USA. It is also associated with high morbidity, and poses an enormous burden of suffering and expense. Despite this, the disease has received little attention compared with other respiratory conditions such as asthma and lung cancer.
Current treatment can offer some marginal symptomatic relief but does not address the underlying disease process. Indeed, smoking cessation is the only intervention known to alter the rate of disease progression. There is clearly great need, and potential, for the development of superior therapies for symptomatic relief and disease modification. This book brings together leading researchers and physicians to discuss the most recent advances in our understanding of COPD, and draws together basic and clinical aspects relevant to the topic. Coverage includes the basic pathology, current and potential therapies, and detailed consideration of the major theories for the pathogenesis of COPD.
Arvustused
"The panel of speakers included some of the most distinguished scientists and physicians working in the field of COPD." (Biochemie, No. 83, 2001)
Symposium on Chronic obstructive pulmonary disease: pathogenesis to treatment, held at the Novartis Foundation, London, 25-27 January 2000 Derek Chadwick Jamie A. Goode Paul Nicklin Judy Phillips Introduction 1(3) William MacNee Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis 4(23) James C. Hogg Discussion 19(8) Overview of current therapies 27(18) Peter M. A. Calverley Discussion 34(11) Genetics of chronic obstructive pulmonary disease 45(20) Edwin K. Silverman Discussion 58(7) Mucus hypersecretion in chronic obstructive pulmonary disease 65(19) Duncan F. Rogers Discussion 77(7) Mechanisms of exacerbations 84(20) Jadwiga A. Wedzicha Discussion 93(11) Epithelial cells and fibroblasts 104(16) Stephen I. Rennard Discussion 112(8) Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines 120(16) Alberto Mantovani Marta Muzio Cecilia Garlanda Silvano Sozzani Paola Allavena Discussion 132(4) Neutrophils in chronic obstructive pulmonary disease 136(13) Timothy J. Williams Peter J. Jose Discussion 141(8) Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease 149(20) Peter K. Jeffery Discussion 161(8) Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy 169(20) William MacNee Discussion 185(4) Proteases and antiproteases 189(16) Robert A. Stockley Discussion 199(6) Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease 205(24) Tim Cawston Severine Carrere Jon Catterall Richard Duggleby Sarah Elliott Bill Shingleton Andrew Rowan Discussion 218(11) Pulmonary alveolus formation: critical period, retinoid regulation and plasticity 229(13) Donald Massaro Gloria DeCarlo Massaro Discussion 236(6) Systemic effects of chronic obstructive pulmonary disease 242(13) Alvar G. N. Agusti Discussion 250(5) Potential novel therapies for chronic obstructive pulmonary disease 255(18) Peter J. Barnes Discussion 267(6) Closing remarks 273(3) William MacNee Index of contributors 276(2) Subject index 278
Derek J. Chadwick and Jamie A. Goode are editors for Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment and other scientific titles.
